List of Lotemax Sm drug patents
Lotemax Sm is owned by Bausch And Lomb Inc.
Lotemax Sm contains Loteprednol Etabonate.
Lotemax Sm has a total of 2 drug patents out of which 0 drug patents have expired.
Lotemax Sm was authorised for market use on 22 February, 2019.
Lotemax Sm is available in gel;ophthalmic dosage forms.
Lotemax Sm can be used as treatment of post-operative inflammation and pain following ocular surgery.
The generics of Lotemax Sm are possible to be released after 23 December, 2036.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11534395 | BAUSCH AND LOMB INC | Ophthalmic suspension composition |
Jan, 2036
(12 years from now) | |
| US10596107 | BAUSCH AND LOMB INC | Ophthalmic suspension composition |
Dec, 2036
(13 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Strength (NS) | Feb 22, 2022 |
Drugs and Companies using LOTEPREDNOL ETABONATE ingredient
Market Authorisation Date: 22 February, 2019
Treatment: Treatment of post-operative inflammation and pain following ocular surgery
Dosage: GEL;OPHTHALMIC
LOTEMAX SM family patents
4
United States
4
European Union
3
Hungary
3
Spain
3
Poland
2
Australia
1
Canada
1
Mexico
1
Brazil
1
China
1
Portugal
1
Japan
1
Korea, Republic of
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic